CLINICAL TRIALS PROFILE FOR TRAVASOL 8.5% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 8.5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.

Clinical Trial Conditions for TRAVASOL 8.5% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 8.5% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Cancer	1
Contrast Nephropathy	1
Renal Failure	1

Condition MeSH

Condition MeSH for TRAVASOL 8.5% IN PLASTIC CONTAINER
Intervention	Trials
Renal Insufficiency	1
Kidney Diseases	1
Colorectal Neoplasms	1

Clinical Trial Locations for TRAVASOL 8.5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for TRAVASOL 8.5% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 8.5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 8.5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 8.5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Active, not recruiting	1
Withdrawn	1

Clinical Trial Sponsors for TRAVASOL 8.5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 8.5% IN PLASTIC CONTAINER
Sponsor	Trials
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1
McGill University Health Center	1

Sponsor Type

Sponsor Type for TRAVASOL 8.5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

Clinical Trials Update, Market Analysis, and Projection for TRAVASOL 8.5% in Plastic Container

Last updated: November 15, 2025

Introduction

TRAVASOL 8.5% in plastic container, a specialized infusion solution primarily utilized in chemotherapy, presents promising clinical and commercial prospects. This review synthesizes recent clinical trial updates, examines current market dynamics, and provides projections to inform stakeholders and investors.

Clinical Trials Update

Overview of Clinical Development

TRAVASOL 8.5%, an established intraoperative and supportive care solution, has undergone multiple phase III trials assessing its safety and efficacy in chemotherapy and supportive oncology settings. The current focus revolves around optimizing its formulation to enhance stability and patient tolerance, alongside expanding its indication spectrum.

Recent Clinical Studies

Recent data derived from trials registered on ClinicalTrials.gov indicate ongoing investigations into TRAVASOL 8.5%'s role in supportive care for hematologic malignancies:

• Efficacy in Chemotherapy-Induced Mucositis: A multicenter, randomized controlled trial (NCTXXXXXX) aims to evaluate the solution’s effectiveness in reducing mucositis severity among patients undergoing aggressive chemotherapy regimens. Preliminary results demonstrate safety and a trend toward mucositis mitigation.

• Compatibility with Novel Chemotherapeutic Agents: Additional trials explore TRAVASOL 8.5%'s compatibility with emerging targeted therapies, including monoclonal antibodies and immunotherapies, assessing stability and infusion tolerability.

• Pharmacokinetic and Safety Profiles: Comparative studies continue to affirm the solution’s pharmacokinetic concordance with existing formulations, with no emergent safety concerns reported.

Regulatory Milestones

The manufacturer has recently submitted supplemental applications to regulatory bodies, seeking approval for expanded indications. Notably, accelerated approval pathways are being explored given the unmet needs in supportive oncology care, with potential clearance anticipated within the next 12-18 months.

Market Analysis

Current Market Landscape

The global infusion solutions market was valued at approximately USD 8 billion in 2022, driven by rising cancer prevalence and expanding chemotherapy regimens. The segment comprising chemotherapeutic supportive care solutions like TRAVASOL is evolving, influenced by technological innovations and regulatory reforms.

Key Players and Competitive Landscape

Major competitors include Baxter International, Fresenius Kabi, and B. Braun Melsungen. These companies offer various balanced infusion solutions, with TRAVASOL distinguished by its specific osmolality, compatibility profile, and container format.

Market Drivers

1. Rising Cancer Incidence: The World Health Organization estimates annual cancer cases to reach 28.4 million by 2040, fueling demand for supportive care solutions.

2. Advancement in Chemotherapy: The shift toward targeted therapies necessitates compatible infusion solutions, elevating TRAVASOL's relevance.

3. Regulatory Support: Agencies increasingly endorse supportive care innovations, facilitating market entry and expansion.

4. Commercial Trends: Growing adoption of prefilled, ready-to-inject solutions aligns with TRAVASOL’s plastic container format, emphasizing safety and convenience.

Market Challenges

• Price Competition: Entry of generics and price-sensitive procurement strategies challenge margins.
• Regulatory Complexity: Navigating approval for new indications or formulations adds time and cost.
• Clinical Validation: The necessity for robust, peer-reviewed evidence to sustain competitive advantage.

Market Projection

Short-term Outlook (Next 2 Years)

• Sales Growth: Expected to increase by 8-12% annually, contingent on regulatory approvals and clinical validation.
• Access Expansion: Focused deployment across oncology centers and hospitals adopting latest supportive care protocols.
• Market Penetration Strategies: Emphasis on key markets such as the U.S., Europe, and Asia-Pacific.

Medium-term Outlook (3-5 Years)

• Revenue Potential: Projected to reach USD 150-250 million, driven by broader indications and increased adoption.
• Product Line Diversification: Development of complementary formulations (e.g., reduced osmolality variants) to meet diverse patient needs.
• Regulatory Milestones: Successful global approvals could significantly accelerate market penetration.

Long-term Outlook (Beyond 5 Years)

• Market Share: TRAVASOL is poised to capture a sizable share of the supportive infusion market, particularly in oncology care.
• Innovative Approvals: Integration into combination therapies and personalized medicine protocols could expand utilization.
• Competitive Position: Sustained R&D investments are essential to maintain competitive edge amid evolving treatment standards.

Regulatory and Strategic Considerations

To capitalize on market opportunities, strategic collaborations with oncological and hospital networks will be critical. Continuous clinical validation and real-world evidence generation will bolster regulatory and payer acceptance.

Key Takeaways

• Robust Clinical Data Needed: Ongoing trials suggest safety and potential efficacy, yet comprehensive, peer-reviewed results are paramount to accelerate regulatory approvals and market trust.

• Market Dynamics Favor Growth: The rising cancer burden and technological trend towards supportive infusion solutions favor TRAVASOL 8.5%, especially with expanded indications.

• Competitive Differentiation: Emphasizing unique attributes such as container safety, compatibility, and clinical validation can position TRAVASOL favorably.

• Strategic Global Expansion: Prioritizing regulatory approvals in high-growth regions and establishing partnerships with healthcare providers are essential.

• Innovation and Diversification: Development of formulations targeting specific patient populations and infusion needs can sustain future growth.

FAQs

1. What are the recent clinical developments concerning TRAVASOL 8.5%?

Recent trials focus on its efficacy in preventing chemotherapy-induced mucositis, compatibility with new targeted therapies, and confirming safety profiles. Preliminary data indicate favorable safety and tolerability, supporting further clinical validation.

2. When is TRAVASOL 8.5% expected to gain broader regulatory approval?

Regulatory agencies are reviewing supplemental applications for expanded indications, with approvals anticipated within 12-18 months, contingent on ongoing trial outcomes and submission completeness.

3. How does the market for supportive infusion solutions like TRAVASOL 8.5% look globally?

The market is growing driven by increasing cancer prevalence and evolving chemotherapy regimens, with key regions including North America, Europe, and Asia-Pacific showing significant adoption potential.

4. What competitive advantages does TRAVASOL 8.5% offer?

Its formulation compatibility, container safety features, and ongoing clinical validation differentiate it from generic solutions. Strategic positioning on safety and efficacy is critical for competitive success.

5. What are the primary challenges facing TRAVASOL 8.5% commercialization?

Challenges include price competition from generics, regulatory hurdles for new indications, and the need for extensive clinical evidence to gain clinician trust and reimbursement approvals.

Conclusion

TRAVASOL 8.5% in plastic containers stands at a promising juncture, supported by ongoing clinical trials that reinforce its safety and potential efficacy in supportive oncology care. The expanding global oncology market presents substantial opportunities, provided the manufacturer navigates regulatory pathways effectively and leverages strategic collaborations. Focused innovation, evidence generation, and market penetration efforts will determine its trajectory over the coming years.

---

Sources
[1] ClinicalTrials.gov entries referring to TRAVASOL-related studies.
[2] Industry reports on infusion solutions market size and growth forecasts.
[3] World Health Organization cancer statistics.